Serum level of matrix metalloproteinase 3 (stromelysin 1) in patients with systemic lupus erythematosus: relation to clinical nephritis and neuropsychiatric manifestations
Aim The aim of this study was to assess serum matrix metalloproteinase 3 (MMP-3) level in patients of systemic lupus erythematosus (SLE) and its relation to various clinical and laboratory findings. Patients and methods The study involved 40 female patients with SLE as a study group and 20 sex-match...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
General Organization of Teaching Hospitals and Institutes
2019-01-01
|
| Series: | Journal of Medicine in Scientific Research |
| Subjects: | |
| Online Access: | http://www.jmsr.eg.net/article.asp?issn=2537-091X;year=2019;volume=2;issue=2;spage=101;epage=106;aulast=M. |
| _version_ | 1827296402133221376 |
|---|---|
| author | Taghreed F M. Mostafa Fatema A Elshabacy Lobna Y Ebrahim Eman R Amer Hala A Elhameed Tabl |
| author_facet | Taghreed F M. Mostafa Fatema A Elshabacy Lobna Y Ebrahim Eman R Amer Hala A Elhameed Tabl |
| author_sort | Taghreed F M. Mostafa |
| collection | DOAJ |
| description | Aim
The aim of this study was to assess serum matrix metalloproteinase 3 (MMP-3) level in patients of systemic lupus erythematosus (SLE) and its relation to various clinical and laboratory findings.
Patients and methods
The study involved 40 female patients with SLE as a study group and 20 sex-matched and age-matched healthy individuals as a control group. All patients were subjected to thorough clinical examinations and laboratory investigations. Disease activity was assessed using SLE Disease Activity Index, as well as Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index. Serum level of MMP-3 was assessed using enzyme-linked immunosorbent assay technique. Patients who showed clinical manifestations of neuropsychiatric lupus were subjected to brain MRI.
Results
The mean serum MMP-3 was significantly higher in patients with SLE than controls (24.93 ± 21.67 vs. 6.98 ± 1.85,P < 0.001) and in patients with nephritis or cerebritis than patients presented with other clinical features (P = 0.009 and 0.018, respectively). Serum MMP-3 was significantly positively correlated with SLE Disease Activity Index (P = 0.001) and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (P = 0.02) as well as laboratory markers of disease activity such as anti-double-stranded DNA antibodies and erythrocyte sedimentation rate (P < 0.001). Patients with neuropsychiatric lupus showed normal MRI brain findings, except one 21-year-old female patient who presented with psychosis showed atrophic changes. MMP-3 at cutoff of at least 26.7 μg/ml can significantly predict patients with nephritis with sensitivity of 77.8% and specificity of 95.5%; area under the curve was 0.842.
Conclusion
MMP-3 was reported to be higher in patients with SLE than controls and patients who presented with either nephritis or neuropsychiatric symptoms showed elevated level of MMP-3 than patients presented with other clinical manifestations. In addition to its proven role in development of lupus nephritis, this study highlighted the possible role of MMP-3 in neuropsychiatric disease. |
| first_indexed | 2024-04-24T14:38:10Z |
| format | Article |
| id | doaj.art-150f76a0232e4b7ea339a7b7596632db |
| institution | Directory Open Access Journal |
| issn | 2537-091X 2537-0928 |
| language | English |
| last_indexed | 2024-04-24T14:38:10Z |
| publishDate | 2019-01-01 |
| publisher | General Organization of Teaching Hospitals and Institutes |
| record_format | Article |
| series | Journal of Medicine in Scientific Research |
| spelling | doaj.art-150f76a0232e4b7ea339a7b7596632db2024-04-02T22:58:27ZengGeneral Organization of Teaching Hospitals and InstitutesJournal of Medicine in Scientific Research2537-091X2537-09282019-01-012210110610.4103/JMISR.JMISR_27_19Serum level of matrix metalloproteinase 3 (stromelysin 1) in patients with systemic lupus erythematosus: relation to clinical nephritis and neuropsychiatric manifestationsTaghreed F M. MostafaFatema A ElshabacyLobna Y EbrahimEman R AmerHala A Elhameed TablAim The aim of this study was to assess serum matrix metalloproteinase 3 (MMP-3) level in patients of systemic lupus erythematosus (SLE) and its relation to various clinical and laboratory findings. Patients and methods The study involved 40 female patients with SLE as a study group and 20 sex-matched and age-matched healthy individuals as a control group. All patients were subjected to thorough clinical examinations and laboratory investigations. Disease activity was assessed using SLE Disease Activity Index, as well as Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index. Serum level of MMP-3 was assessed using enzyme-linked immunosorbent assay technique. Patients who showed clinical manifestations of neuropsychiatric lupus were subjected to brain MRI. Results The mean serum MMP-3 was significantly higher in patients with SLE than controls (24.93 ± 21.67 vs. 6.98 ± 1.85,P < 0.001) and in patients with nephritis or cerebritis than patients presented with other clinical features (P = 0.009 and 0.018, respectively). Serum MMP-3 was significantly positively correlated with SLE Disease Activity Index (P = 0.001) and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (P = 0.02) as well as laboratory markers of disease activity such as anti-double-stranded DNA antibodies and erythrocyte sedimentation rate (P < 0.001). Patients with neuropsychiatric lupus showed normal MRI brain findings, except one 21-year-old female patient who presented with psychosis showed atrophic changes. MMP-3 at cutoff of at least 26.7 μg/ml can significantly predict patients with nephritis with sensitivity of 77.8% and specificity of 95.5%; area under the curve was 0.842. Conclusion MMP-3 was reported to be higher in patients with SLE than controls and patients who presented with either nephritis or neuropsychiatric symptoms showed elevated level of MMP-3 than patients presented with other clinical manifestations. In addition to its proven role in development of lupus nephritis, this study highlighted the possible role of MMP-3 in neuropsychiatric disease.http://www.jmsr.eg.net/article.asp?issn=2537-091X;year=2019;volume=2;issue=2;spage=101;epage=106;aulast=M.matrix metalloproteinase 3nephritisneuropsychiatric lupussystemic lupus erythematosus |
| spellingShingle | Taghreed F M. Mostafa Fatema A Elshabacy Lobna Y Ebrahim Eman R Amer Hala A Elhameed Tabl Serum level of matrix metalloproteinase 3 (stromelysin 1) in patients with systemic lupus erythematosus: relation to clinical nephritis and neuropsychiatric manifestations Journal of Medicine in Scientific Research matrix metalloproteinase 3 nephritis neuropsychiatric lupus systemic lupus erythematosus |
| title | Serum level of matrix metalloproteinase 3 (stromelysin 1) in patients with systemic lupus erythematosus: relation to clinical nephritis and neuropsychiatric manifestations |
| title_full | Serum level of matrix metalloproteinase 3 (stromelysin 1) in patients with systemic lupus erythematosus: relation to clinical nephritis and neuropsychiatric manifestations |
| title_fullStr | Serum level of matrix metalloproteinase 3 (stromelysin 1) in patients with systemic lupus erythematosus: relation to clinical nephritis and neuropsychiatric manifestations |
| title_full_unstemmed | Serum level of matrix metalloproteinase 3 (stromelysin 1) in patients with systemic lupus erythematosus: relation to clinical nephritis and neuropsychiatric manifestations |
| title_short | Serum level of matrix metalloproteinase 3 (stromelysin 1) in patients with systemic lupus erythematosus: relation to clinical nephritis and neuropsychiatric manifestations |
| title_sort | serum level of matrix metalloproteinase 3 stromelysin 1 in patients with systemic lupus erythematosus relation to clinical nephritis and neuropsychiatric manifestations |
| topic | matrix metalloproteinase 3 nephritis neuropsychiatric lupus systemic lupus erythematosus |
| url | http://www.jmsr.eg.net/article.asp?issn=2537-091X;year=2019;volume=2;issue=2;spage=101;epage=106;aulast=M. |
| work_keys_str_mv | AT taghreedfmmostafa serumlevelofmatrixmetalloproteinase3stromelysin1inpatientswithsystemiclupuserythematosusrelationtoclinicalnephritisandneuropsychiatricmanifestations AT fatemaaelshabacy serumlevelofmatrixmetalloproteinase3stromelysin1inpatientswithsystemiclupuserythematosusrelationtoclinicalnephritisandneuropsychiatricmanifestations AT lobnayebrahim serumlevelofmatrixmetalloproteinase3stromelysin1inpatientswithsystemiclupuserythematosusrelationtoclinicalnephritisandneuropsychiatricmanifestations AT emanramer serumlevelofmatrixmetalloproteinase3stromelysin1inpatientswithsystemiclupuserythematosusrelationtoclinicalnephritisandneuropsychiatricmanifestations AT halaaelhameedtabl serumlevelofmatrixmetalloproteinase3stromelysin1inpatientswithsystemiclupuserythematosusrelationtoclinicalnephritisandneuropsychiatricmanifestations |